Primary References:
Oxford Textbook of Medicine Chapter 23.1 Diseases of the Skin Copyright
2003 by Oxford University Press
<http://md.skolar.com.laneproxy.stanford.edu/index__.jsp?trg=%2Femr%2FSearch.jsp%3Fquery%3Dpapillomavirus%26resource%3Doup%26resource%3Doup&nav=home>
Fields Virology. p. 2236-2243; 2254-2257
Horng-Jyh et al. An association between human papillomavirus 16/18 deoxyribonucleic acid in peripheral blood with p16 protein expression in neoplastic cervical lesions. Cancer Detection and Protection. 2005
Brenda Y. Hernandez et al. Anal Human Papillomavirus Infection in Women and Its Relationship with Cervical Infection Cancer Epidemiology Biomarkers & Prevention Vol. 14, 2550-2556, November 2005
Insinga, Ralph P.; Dasbach, Erik J.; Elbasha, Elamin H. Assessing the Annual Economic Burden of Preventing and Treating Anogenital Human Papillomavirus-Related Disease in the US: Analytic Framework and Review of the Literature. PharmacoEconomics, 2005, Vol. 23 Issue 11, p1107, 16p
Mohammadreza Barghi et al. Correlation between human papillomavirus infection and bladder transitional cell carcinoma BMC Infectious Diseases 2005, 5:102
C-Y Kan et al. Identification of human papillomavirus DNA gene sequences in human breast cancer. British Journal of Cancer (2005) 93, 946 – 948
Arias-Pulido H, Peyton CL, Torrez-Martinez N, et al. Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology. 2005 Jul 20;338(1):22-34.
Villa LL, Schlegel R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology. 1991 Mar;181(1):374-7.
Riethdorf S, Riethdorf L, Milde-Langosch K, et al. Differences in HPV 16- and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinomas of the cervix uteri. Virchows Arch. 2000 Nov;437(5):491-500.
Santin AD, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol. 2005 Oct 21